Table 3 Baseline characteristics of AAV patients with and without excessive B cell differentiation by treatment group
Variables | Rituximab group, n = 34 | IV-CY group, n = 20 | p value | ||
|---|---|---|---|---|---|
Excessive B cell differentiation | + | − | + | − | |
n (%) | 16 (24.1%) | 18 (27.6%) | 8 (14.8%) | 12 (22.2%) | |
Age (years) | 71.6 (8.3) | 69.6 (9.5) | 69.4 (8.6) | 71.7 (7.8) | 0.83 |
Gender, n (% female) | 8 (57.1%) | 11 (68.8%) | 4 (44.4%) | 8 (42.1%) | 0.67 |
Disease duration (month) | 2 (2–4) | 3 (1–7) | 3 (2–7) | 4 (1–6) | 0.70 |
New onset, n (%) | 16 (100.0%) | 18 (100.0%) | 8 (100.0%) | 12 (100.0%) | 1.00 |
ANCA-positive at diagnosis, n (%) | |||||
Proteinase 3 ANCA | 3 (18.8%) | 1 (5.6%) | 0 (0.0%) | 0 (0.0%) | 0.15 |
Myeloperoxidase-ANCA | 11 (68.8%) | 15 (83.3%) | 7 (87.5%) | 11 (91.7%) | 0.43 |
Proteinase 3 + myeloperoxidase-ANCA | 1 (6.3%) | 2 (11.1%) | 1 (12.5%) | 0 (0.0%) | 0.65 |
ANCA-associated vasculitis type, n (%) | 0.35 | ||||
MPA | 8 (50.0%) | 11 (61.1%) | 7 (87.5%) | 8 (66.7%) | |
GPA | 8 (50.0%) | 7 (38.9%) | 1 (12.5%) | 4 (33.3%) | |
BVAS | 18.0 (5.6) | 16.9 (7.3) | 14.5 (4.5) | 15.4 (4.8) | 0.50 |
GC dose at baseline | 54.6 (11.0) | 57.7 (12.1) | 62.5 (22.4) | 61.0 (12.8) | 0.51 |